Oral 5-Fluorouracil in Psoriasis: Pharmacokinetic-Pharmacodynamic Relationships
- 1 January 1989
- journal article
- research article
- Published by S. Karger AG in Pharmacology
- Vol. 39 (2), 78-88
- https://doi.org/10.1159/000138581
Abstract
Previous studies have suggested oral 5-fluorouracil (5-FU) is unpredictably and erratically absorbed. We studied oral pharmacokinetics of 5-FU in 16 patients (aged 34–71 years) with severe recalcitrant psoriasis. Each patient received repeated single oral doses of 5-FU, each separated by 1 week. Doses were ascending (300, 600, 900, 1,200 mg/m2), and after the first 3 patients, doses were started at 600 mg/m2 and increased. Multiple blood samples were obtained after each 5-FU dose and plasma 5-FU concentration determined by HPLC. Response was determined by clinical assessment of skin thickening, redness, and scaling on upper and lower body and quantified as percent improvement. Among all patients total dose and total area under the plasma 5-FU concentration-time curve (AUC) was significantly related (r = 0.65; p < 0.01). In contrast no relationship between either total 5-FU dose and response (r = –0.07) or AUC and response (r = –0.08) was identified. With each individual patient, total 5-FU dose and response were well correlated in 11 of 14 patients (r = 0.96, 0.92, 0.92, 0.97, 0.78, 0.85, 0.71, 0.89, 0.96, 0.76, 0.94) and less well related in 3 of 14 (r = 0.57, 0.51, 0.15). Similarly, cumulative 5-FU AUC and response were well correlated in 11 of 14 patients (r = 0.91, 0.84, 0.83, 0.91, 0.77, 0.86, 0.75, 0.93, 0.99, 0.74, 0.89) and less well related in the same 3 patients (r = 0.61, 0.40, 0.03). The relationship of the 5-FU dose and AUC was nonlinear with normalized dose: AUC 1.0 at the lowest dose for each patient, at 1.5 dose AUC was 3.4 times baseline, at 2.0 dose AUC was 5.3 times baseline, and at 3.0 dose AUC was 36 times baseline. In patients with recalcitrant psoriasis 5-FU is consistently absorbed into the systemic circulation with extent of absorption increased with increasing dose in a nonlinear manner. Evaluation of both total 5-FU dose and total 5-FU AUC indicates a clear within-patient dose and AUC:response relationship.Keywords
This publication has 14 references indexed in Scilit:
- STEADY-STATE NONLINEAR PHARMACOKINETICS OF 5-FLUOROURACIL DURING HEPATIC ARTERIAL AND INTRAVENOUS INFUSIONS IN CANCER-PATIENTS1986
- Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography.Journal of Biological Chemistry, 1982
- A Rapid High-Performance Liquid Chromatographic Method for Quantitation of 5-Fluorouracil in Plasma after Continuous Intravenous InfusionAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1982
- Pharmacokinetics of oral and intravenous fluorouracil in humansJournal of Pharmaceutical Sciences, 1980
- Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routesClinical Pharmacology & Therapeutics, 1980
- Pharmacokinetic Studies of 5‐Fluorouracil after Oral and Intravenous Administration in ManActa Pharmacologica et Toxicologica, 1980
- REGULATION OF RNA-DIRECTED AND DNA-DIRECTED ACTIONS OF 5-FLUOROPYRIMIDINES IN MOUSE T-LYMPHOMA (S-49) CELLS1980
- BASIS FOR NATURAL VARIATION IN SENSITIVITY TO 5-FLUOROURACIL IN MOUSE AND HUMAN CELLS IN CULTURE1979
- Fluorouracil Therapy in Patients With Carcinoma of the Large BowelClinical Pharmacokinetics, 1978
- Pharmacokinetics of 5-FluorouracilClinical Pharmacokinetics, 1977